This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Age: 48 - 69 months
Gender: All
We've found 1 total result for "Hyperkinesis".
We've found 1 total result for "Hyperkinesis".
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Age: 48 - 69 months
Gender: All